College of Chemistry & Chemical Engineering, Central South University, Changsha, Hunan, China.
Luminescence. 2024 Nov;39(11):e70028. doi: 10.1002/bio.70028.
Abnormal lysosomal viscosity is closely associated with cancer progression, underscoring the need for bifunctional fluorescent probes and photosensitizers (PSs) that can both monitor viscosity and facilitate imaging-guided therapy for simultaneous cancer diagnosis and treatment. Despite advances in lysosome-targeted PSs development, few have demonstrated the ability to generate both Type I and Type II reactive oxygen species (ROS). In this study, we present BTTPA, a lysosome-targeted fluorescent probe and photosensitizer, designed to integrate cancer diagnosis via viscosity imaging and cancer treatment through photodynamic therapy (PDT). Our findings reveal that BTTPA selectively targets lysosomes, enabling dynamic monitoring of cellular viscosity and distinguishing cancer cells from normal cells. Upon light activation, BTTPA efficiently generates both Type I and Type II ROS. Apoptosis assays further confirm BTTPA's effectiveness in inducing cancer cell apoptosis, highlighting its potential as a powerful tool for cancer diagnosis and therapy.
异常溶酶体黏度与癌症进展密切相关,这凸显了对能够同时监测黏度和促进成像引导治疗的双功能荧光探针和光敏剂(PSs)的需求,以实现癌症的诊断和治疗。尽管在溶酶体靶向 PSs 的开发方面取得了进展,但很少有研究能够同时产生 I 型和 II 型活性氧(ROS)。在这项研究中,我们提出了 BTTPA,这是一种溶酶体靶向荧光探针和光敏剂,旨在通过黏度成像进行癌症诊断,并通过光动力疗法(PDT)进行癌症治疗。我们的研究结果表明,BTTPA 选择性地靶向溶酶体,能够动态监测细胞黏度,并区分癌细胞和正常细胞。在光激活后,BTTPA 能够有效地产生 I 型和 II 型 ROS。凋亡实验进一步证实了 BTTPA 诱导癌细胞凋亡的有效性,突出了其作为癌症诊断和治疗的有力工具的潜力。